Pheast Therapeutics revealed the initial showcasing of preclinical data for PHST001, an anti-CD24 antibody drug candidate.

Azitra, Inc. Reveals Encouraging Preclinical Data on ATR-12 and Clinical Plan for Netherton Syndrome at ASGCT Annual Conference.

Eisai Begins Submission of Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) Subcutaneous Maintenance Dosing in Early Alzheimer's, Fast Track Status.

PTC Therapeutics, Inc. revealed today that the FDA has officially received the Biologics License Application for Upstaza™ (eladocagene exuparvovec), a gene therapy aimed at treating AADC deficiency.

Verismo Therapeutics announced that the FDA has approved a Phase 1 clinical trial for SynKIR™-310 to evaluate its effectiveness for NHL.

This approval allows for the commencement of the Phase 3 Polaris-AD trial for AR1001 in early Alzheimer's Disease in China starting May 11th, 2024.

Fulcrum Therapeutics and Sanofi sign an agreement for Losmapimod's development and marketing in treating Facioscapulohumeral Muscular Dystrophy.

Senti Bio reports initial dosing in a Phase 1 trial for SENTI-202, targeting recurrent or treatment-resistant blood cancers like Acute Myeloid Leukemia.

Novo Nordisk A/S reports that in the Frontier 2 study, their once-weekly and once-monthly Mim8 treatments significantly outperformed standard and prior prophylaxis treatments in reducing bleeding episodes in individuals with haemophilia A.

Mabwell reported progress in its clinical trial of the novel Nectin-4 targeting ADC (9MW2821) for triple-negative breast cancer treatment.

AC Immune and Takeda Enter an Exclusive Deal for Licence and Option on Active Immunotherapy Focused on Amyloid Beta for Alzheimer's Disease.

Kodiak Sciences has started treating initial participants in the Phase 3 GLOW2 study, examining Tarcocimab Tedromer for diabetic retinopathy.